CHMP recommends EU approval of Roche's Subcutaneous Herceptin for HER2 positive breast cancer

- New injectable administration takes two to five minutes, rather than 30 to 90 minutes with the current intravenous form, potentially saving both healthcare resources and patients' time - Herceptin® is a personalised medicine used to treat more than 80,000 HER2-positive breast cancer patients in Europe each year
Source: Roche Media News - Category: Pharmaceuticals Source Type: news